ATE79271T1 - Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. - Google Patents

Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.

Info

Publication number
ATE79271T1
ATE79271T1 AT86104562T AT86104562T ATE79271T1 AT E79271 T1 ATE79271 T1 AT E79271T1 AT 86104562 T AT86104562 T AT 86104562T AT 86104562 T AT86104562 T AT 86104562T AT E79271 T1 ATE79271 T1 AT E79271T1
Authority
AT
Austria
Prior art keywords
bone mass
enhancement
application
pharmaceutical preparation
afflicted
Prior art date
Application number
AT86104562T
Other languages
English (en)
Inventor
John T Potts Jr
Robert M Neer
David M Slovik
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24892318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79271(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE79271T1 publication Critical patent/ATE79271T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86104562T 1985-04-04 1986-04-03 Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. ATE79271T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72001885A 1985-04-04 1985-04-04
EP86104562A EP0197514B1 (de) 1985-04-04 1986-04-03 Pharmazeutische Zubereitung zur Anwendung für die Anreicherung von Knochenmasse

Publications (1)

Publication Number Publication Date
ATE79271T1 true ATE79271T1 (de) 1992-08-15

Family

ID=24892318

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86104562T ATE79271T1 (de) 1985-04-04 1986-04-03 Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.

Country Status (12)

Country Link
US (1) US4698328A (de)
EP (1) EP0197514B1 (de)
JP (2) JPH0772138B2 (de)
AT (1) ATE79271T1 (de)
AU (1) AU599905B2 (de)
CA (1) CA1288695C (de)
DE (1) DE3686343T2 (de)
DK (1) DK172816B1 (de)
IE (1) IE59620B1 (de)
IL (1) IL78342A (de)
PH (1) PH23720A (de)
ZA (1) ZA862510B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3725319A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Pth-modifikationen und therapeutische zusammensetzungen, die sie enthalten und daraus bestehen
EP0318184A1 (de) * 1987-11-12 1989-05-31 Schering Corporation Knochenbildungbeschleunigung durch GM-CSF
JPH07110809B2 (ja) * 1987-11-18 1995-11-29 帝人株式会社 更年期障害の治療薬
IL89392A (en) * 1988-03-23 1993-02-21 Teva Pharmaceutical Ind Ltd Je Compositions for the treatment of osteoporosis in humans comprising 24, 25-dihydroxy-vitamin d3
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
CA1341408C (en) * 1988-08-02 2002-12-10 Charles W. Bishop Method for treating and preventing loss of bone mass
US4942036A (en) * 1988-08-25 1990-07-17 Blair Geho W Therapy by vesicle delivery to the hydroxyapatite of bone
DE4026146A1 (de) * 1990-08-17 1992-02-20 Biotechnolog Forschung Gmbh Mittregionale pth fragmente in kombination mit 1,25(oh)(pfeil abwaerts)2(pfeil abwaerts)(pfeil hoch)d(pfeil hoch)(pfeil abwaerts)3(pfeil abwaerts) bewirken einen anabolen effekt (calciumeinbau) auf den knochen
HUT64565A (en) * 1990-12-13 1994-01-28 Genentech Inc Method for producing compounds and preparatives inhibiting resorption of bones
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
CA2098639A1 (en) * 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
TW303299B (de) * 1993-07-22 1997-04-21 Lilly Co Eli
US5763429A (en) 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
AU750451B2 (en) 1997-02-13 2002-07-18 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
DZ2873A1 (fr) * 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
WO2000023594A1 (en) * 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
ATE384743T1 (de) * 1998-11-25 2008-02-15 Gen Hospital Corp Aminoterminal modifizierte parathyroidhormon (pth) analoge
WO2000039278A2 (en) * 1998-12-31 2000-07-06 The General Hospital Corporation Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US7057012B1 (en) 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
EP1221966B1 (de) * 1999-09-20 2005-11-16 Eli Lilly And Company Verwendung einer parathyroidhormone zur reduktion des krebsrisikos
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
DE60040678D1 (en) 1999-09-29 2008-12-11 Gen Hospital Corp Parathyroid hormon (pth) polypeptidderivate
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
IL153378A0 (en) 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
AU2002211629A1 (en) * 2000-10-10 2002-04-22 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
WO2003009804A2 (en) * 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
WO2004067021A1 (en) * 2003-01-24 2004-08-12 Gardella Thomas J Conformationally constrained parathyroid hormone (pth) analogs with lactam bridges
WO2004093902A1 (en) * 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
WO2005016265A2 (en) * 2003-08-06 2005-02-24 Rhodia Inc. Method for promoting bone growth
WO2005027915A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
JP4815752B2 (ja) * 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
JP5007427B2 (ja) * 2004-05-13 2012-08-22 アルザ コーポレイション 副甲状腺ホルモン剤の経皮送達のための装置および方法
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
CA2595457A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
BRPI0618469A2 (pt) * 2005-11-10 2011-08-30 Univ Michigan Tech hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
CN101784281B (zh) 2007-08-01 2014-07-02 总医院有限公司 确定g蛋白偶联受体激动剂的方法
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
US9418415B2 (en) * 2014-02-05 2016-08-16 Shimadzu Corporation Trabecular bone analyzer
CN110236710A (zh) * 2018-03-09 2019-09-17 中日友好医院 一种促进植骨材料在牙种植上颌窦外提升术后成骨的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956260A (en) * 1967-11-09 1976-05-11 Ciba-Geigy Corporation Hypocalcaemic peptides and processes for their manufacture
US4241051A (en) * 1977-11-04 1980-12-23 Christie Robert B Calcitonin
JPS55139320A (en) * 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose

Also Published As

Publication number Publication date
IL78342A (en) 1991-06-10
AU5561686A (en) 1986-10-09
AU599905B2 (en) 1990-08-02
US4698328A (en) 1987-10-06
DK155686A (da) 1986-10-05
PH23720A (en) 1989-11-03
DK155686D0 (da) 1986-04-04
ZA862510B (en) 1986-11-26
JPH0772138B2 (ja) 1995-08-02
JPS6233A (ja) 1987-01-06
CA1288695C (en) 1991-09-10
IE59620B1 (en) 1994-03-09
DE3686343T2 (de) 1993-01-28
EP0197514A1 (de) 1986-10-15
DK172816B1 (da) 1999-08-02
DE3686343D1 (de) 1992-09-17
EP0197514B1 (de) 1992-08-12
IE860891L (en) 1986-10-04
JPH07179358A (ja) 1995-07-18
JP2531505B2 (ja) 1996-09-04

Similar Documents

Publication Publication Date Title
DE3686343D1 (de) Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
NO942241L (de)
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
ATE75945T1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
ES2044947T4 (es) Metodo para fabricar una composicion farmaceutica para el tratamiento de la osteoporosis y otras enfermedades oseas.
DK183389A (da) Fremgangsmaade til fremstilling af en administrerings- og/eller doseringsform for medicinsk aktive materialer
DE3166111D1 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
ES2041647T3 (es) Metodo para producir un compuesto de oseinahidroxiapatita.
DE69816808D1 (de) Somatostatin agoniste zur reduzierung von körpergewicht
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
KR980700083A (ko) 골다공증 치료 주기용 키트(KIT for Osteoporosis Treatment Cycle)
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона
CO4700476A1 (es) Metodo para el tratamiento de osteoporosis usando compuestos antiresortivos y hormonas paratiroidales
CO4700481A1 (es) Metodo para el tratamiento de osteoporosis usando compuestos estrogenos y hormonas paratiroidales
BR0008577A (pt) Utilização de hormÈnios sexuais para a obtenção de uma composição farmacêutica nasal útil para o tratamento dos sangramentos uterinos indesejáveis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee